Egypt Cancer Induced Bone Diseases Therapeutics Market Report 2022 to 2030

Egypt Cancer Induced Bone Diseases Therapeutics Market

$ 3999

Egypt Cancer Induced Bone Disease Therapeutics Market valued at $4 Mn in 2022, projected to reach $6 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancer, expanding treatment options, and improved diagnoses. The industry is primarily dominated by players such as EVA, AstraZeneca, Merck, Eli Lilly, Pharco, Johnson & Johnson, Amgen, and Novartis among others.

ID: IN10EGPH440 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Riddhi Solanki

Buy Now

Egypt Cancer Induced Bone Diseases Therapeutics Market Analysis

Egypt Cancer Induced Bone Disease Therapeutics Market valued at $4 Mn in 2022, projected to reach $6 Mn by 2030 with a 7.3% CAGR.

Cancer-induced bone disease refers to a condition that occurs either due to the impact of cancer on the bones or as a result of treatments administered to address the primary condition, resulting in bone loss and fractures. The primary symptom typically includes pain in the bones and joints, along with potential indicators such as swelling, stiffness, or tenderness in the affected bone, difficulties with movement, unexplained weight loss, a fractured bone, loss of sensation in the affected limb, and fatigue. Current treatment options for cancer-related bone disease involve the use of bone-modifying agents like bisphosphonates and denosumab, recognized for their effectiveness in preventing and delaying the emergence of issues related to cancer-induced bone problems. Other treatment modalities comprise surgery, chemotherapy, radiation therapy, targeted therapy, and various drug therapies. Major companies actively engaged in the development and promotion of therapeutics for bone diseases include Amgen, Merck & Co., Roche, Novartis, Eli Lilly and Company, and Bayer AG.

Egypt bears a significant burden of various cancers such as breast cancer, lung cancer, multiple myeloma, and others, resulting in the development of bone metastases. The market is driven by factors such as the increasing incidence of cancer, expanding treatment options, and improved diagnoses. However, conditions such as limited healthcare infrastructure in the country and high costs of treatment limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Rising cancer incidence: Egypt is witnessing an increase in cancer occurrences, with projections indicating a steady increase by the year 2030. This includes cancers such as breast, prostate, and multiple myeloma, all recognized for their association with bone metastases and related conditions. The aging population in Egypt is contributing to a greater proportion of individuals vulnerable to age-related cancers and bone diseases.

Improved diagnoses: Timely identification of cancer and bone-related issues is essential for successful treatment. The increasing acceptance of technologies such as PET scans and bone scintigraphy in Egypt facilitates early detection and intervention.

Expanding treatment options: New targeted drugs and biologics designed specifically for bone metastases and complications are entering the market. These innovations promise enhanced effectiveness and fewer side effects compared to conventional therapies.

Market Restraints

Limited healthcare infrastructure: Medical facilities and experts, especially those capable of advanced cancer diagnosis and treatment, are primarily concentrated in urban regions, leaving rural communities with restricted access. Public healthcare funding faces challenges in keeping up with the increasing demand, resulting in shortages of equipment, medications, and qualified personnel. This shortage can cause delays in diagnosis, restrict treatment choices, and impede access to supportive care for individuals in rural areas.

High cost of treatment: Advanced targeted therapies and biologics designed for the treatment of bone diseases are frequently priced at levels that make them inaccessible to a considerable number of Egyptians, even when covered by insurance. This poses a substantial obstacle to affordability.

Healthcare Policies and Regulatory Landscape

In Egypt, the primary regulatory authority overseeing pharmaceuticals, drugs, and medical products is the Egyptian Drug Authority (EDA). The EDA operates under the Ministry of Health and Population and is responsible for regulating and supervising the pharmaceutical and healthcare products market in the country. It ensures that drugs and medical products meet strict standards of safety, efficacy, and quality before they are approved for sale and distribution in Egypt.

The process of obtaining a license for pharmaceuticals and medical products in Egypt involves submitting a comprehensive application to the Egyptian Drug Authority. For new entrants, entering the pharmaceutical market in Egypt requires a thorough understanding of the regulatory framework and a commitment to meeting stringent requirements. The regulatory environment is designed to uphold high standards, ensuring that only safe and effective products reach the market, but it can present challenges for newcomers who must navigate these processes to bring their products to Egyptian consumers.

Competitive Landscape

Key Players

Roche
Amgen
Novartis
Eli Lilly
Pfizer
EVA Pharma
Pharco Pharmaceuticals
AstraZeneca
Merck& Co
Johnson & Johnson

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Cancer Induced Bone Diseases Therapeutics Market Segmentation

By Cancer Type

Breast cancer
Prostate cancer
Lung cancer
Others

By Treatment Type

Bisphosphonates
Denosumab
Radiation Therapy
Pain Management Medications
Surgical Intervention
Targeted Therapy

By Distribution channel

Hospitals
Pharmacies
Oncology clinics
Others

By Stage of Treatment

Early stage CIBD
Advanced stage CIBD

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.